Melillo, Giovanni
AstraZeneca,
United Kingdom
2025 Rank: 52236
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 2203 out of 355674 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 52236 | 57733 |
| Total Cites | 14169 | 15207 |
| H-index | 48 | 49 |
| Hm-index | 15 | 15 |
| Number of Single Authored Papers | 7 | 7 |
| Total Cites to Single Authored Papers | 435 | 471 |
| Number of Single+First Authored Papers | 17 | 17 |
| Total Cites to Single+First Authored Papers | 1521 | 1680 |
| Number of Single+First+Last Authored Papers | 39 | 39 |
| Total Cites to Single+First+Last Authored Papers | 4403 | 4728 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 11999 | 12586 |
| Ratio of Total Citations to Distinct Citing Papers | 1.18 | 1.21 |
| Self-Citation Percentage |
6.83%
|
|
Melillo, Giovanni
AstraZeneca,
United States
2024 Rank: 49608
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 2135 out of 334837 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 49608 | 54202 |
| Total Cites | 13096 | 14085 |
| H-index | 47 | 49 |
| Hm-index | 15 | 15 |
| Number of Single Authored Papers | 7 | 7 |
| Total Cites to Single Authored Papers | 432 | 468 |
| Number of Single+First Authored Papers | 17 | 17 |
| Total Cites to Single+First Authored Papers | 1501 | 1660 |
| Number of Single+First+Last Authored Papers | 39 | 39 |
| Total Cites to Single+First+Last Authored Papers | 4245 | 4570 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 11089 | 11643 |
| Ratio of Total Citations to Distinct Citing Papers | 1.18 | 1.21 |
| Self-Citation Percentage |
7.02%
|
|
Melillo, Giovanni
AstraZeneca,
United States
2023 Rank: 47228
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 2071 out of 312644 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 47228 | 51183 |
| Total Cites | 11889 | 12829 |
| H-index | 46 | 49 |
| Hm-index | 15 | 15 |
| Number of Single Authored Papers | 7 | 7 |
| Total Cites to Single Authored Papers | 424 | 460 |
| Number of Single+First Authored Papers | 17 | 17 |
| Total Cites to Single+First Authored Papers | 1474 | 1633 |
| Number of Single+First+Last Authored Papers | 39 | 39 |
| Total Cites to Single+First+Last Authored Papers | 4118 | 4443 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 10044 | 10569 |
| Ratio of Total Citations to Distinct Citing Papers | 1.18 | 1.21 |
| Self-Citation Percentage |
7.33%
|
|
Melillo, Giovanni
AstraZeneca,
United States
2022 Rank: 44382
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 1967 out of 293195 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 44382 | 50216 |
| Total Cites | 10500 | 11392 |
| H-index | 45 | 47 |
| Hm-index | 15 | 15 |
| Number of Single Authored Papers | 7 | 7 |
| Total Cites to Single Authored Papers | 414 | 450 |
| Number of Single+First Authored Papers | 17 | 17 |
| Total Cites to Single+First Authored Papers | 1446 | 1594 |
| Number of Single+First+Last Authored Papers | 39 | 39 |
| Total Cites to Single+First+Last Authored Papers | 3956 | 4268 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 8877 | 9371 |
| Ratio of Total Citations to Distinct Citing Papers | 1.18 | 1.22 |
| Self-Citation Percentage |
7.83%
|
|
Melillo, Giovanni
AstraZeneca,
United States
2021 Rank: 42918
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 1917 out of 271773 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 42918 | 48267 |
| Total Cites | 9787 | 10655 |
| H-index | 45 | 47 |
| Hm-index | 15 | 15 |
| Number of Single Authored Papers | 7 | 7 |
| Total Cites to Single Authored Papers | 406 | 442 |
| Number of Single+First Authored Papers | 16 | 16 |
| Total Cites to Single+First Authored Papers | 1409 | 1568 |
| Number of Single+First+Last Authored Papers | 38 | 38 |
| Total Cites to Single+First+Last Authored Papers | 3826 | 4148 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 8305 | 8779 |
| Ratio of Total Citations to Distinct Citing Papers | 1.18 | 1.21 |
| Self-Citation Percentage |
8.15%
|
|
Melillo, Giovanni
AstraZeneca,
United States
2020 Rank: 43936
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 2016 out of 230678 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 43936 | 47320 |
| Total Cites | 7961 | 8737 |
| H-index | 42 | 44 |
| Hm-index | 14 | 15 |
| Number of Single Authored Papers | 7 | 7 |
| Total Cites to Single Authored Papers | 383 | 419 |
| Number of Single+First Authored Papers | 16 | 16 |
| Total Cites to Single+First Authored Papers | 1370 | 1517 |
| Number of Single+First+Last Authored Papers | 38 | 38 |
| Total Cites to Single+First+Last Authored Papers | 3615 | 3924 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 6781 | 7193 |
| Ratio of Total Citations to Distinct Citing Papers | 1.17 | 1.21 |
| Self-Citation Percentage |
8.88%
|
|
Related Profiles
Featured Profiles
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.